Welcome visitor Log In - or - Register
0 items /
View Cart
Check Out
four ways
Quick Search:
Skip Navigation LinksHome > Kinase Inhibitors > c-Met > MGCD265 (Glesatinib)
MGCD265 (Glesatinib)
MGCD265 (Glesatinib) is an orally bioavailable, clinical stage multitargeted tyrosine kinase inhibitor. It binds to and inhibits the phosphorylation of several receptor tyrosine kinases (RTKs), including the c-Met receptor (hepatocyte growth factor receptor); the Tek/Tie-2 receptor; vascular endothelial growth factor receptor (VEGFR) types 1, 2, and 3; and the macrophage-stimulating 1 receptor (MST1R or RON). It is currently being evaluated clinically in patients with solid tumors that have genetic alterations in MET or AXL genes, which have been implicated as drivers of tumor growth and disease progression in NSCLC, gastroesophageal cancer and other solid tumors.
Catalog NO: CT-MG265
Synonym: Glesatinib
CAS NO: 936694-12-1
Mol. Formula: C31H27F2N5O3S2
MW: 619.7 (refer to Certificate of Analysis, batch-specific)
** Buyer Beware: From 2012 to this date (4-20-2016), all other vendors (>20) (no exceptions) have been selling MGCD265 as a wrong structure (with CAS No: 875337-44-3, Mol. Formula: C26H20FN5O2S2, and Mol. Wt: 517.6).